AllianceBernstein
SPRY icon

AllianceBernstein’s ARS Pharmaceuticals SPRY Stock Holding History

AllianceBernstein’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Buy
59,490
+17,510
+42% +$151K ﹤0.01% 2745
2026
Q1 		$489K Sell
41,980
-18,140
-30% -$174K ﹤0.01% 2646
2025
Q4 		$700K Sell
60,120
-2,581,991
-98% -$25.1M ﹤0.01% 2498
2025
Q3 		$26.6M Sell
2,642,111
-1,183,682
-31% -$17M 0.01% 826
2025
Q2 		$66.8M Sell
3,825,793
-97,012
-2% -$1.4M 0.02% 530
2025
Q1 		$49.3M Buy
3,922,805
+42,071
+1% +$506K 0.02% 590
2024
Q4 		$40.9M Buy
3,880,734
+3,807,074
+5,168% +$53.3M 0.01% 656
2024
Q3 		$1.07M Hold
73,660
– – ﹤0.01% 2290
2024
Q2 		$627K Buy
73,660
+14,490
+24% +$129K ﹤0.01% 2539
2024
Q1 		$605K Sell
59,170
-3,620
-6% -$27K ﹤0.01% 2501
2023
Q4 		$344K Hold
62,790
– – ﹤0.01% 2783
2023
Q3 		$237K Buy
62,790
+38,010
+153% +$249K ﹤0.01% 2901
2023
Q2 		$166K Buy
+24,780
New +$165K ﹤0.01% 3018
2021
Q3 		– Sell
-7,300
Closed -$225K – 3336
2021
Q2 		$225K Buy
+7,300
New +$234K ﹤0.01% 3122

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AllianceBernstein's SPRY Position: Q2 2026 in Review

AllianceBernstein increased its ARS Pharmaceuticals (SPRY) stake by 42% in Q2 2026, buying an estimated $151K and bringing the position to 59,490 shares worth $478K. The position accounts for ﹤0.01% of the portfolio, ranked #2745.

AllianceBernstein first reported a position in SPRY in Q2 2021 and has held it in 14 quarters since. The position peaked at $66.8M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • AllianceBernstein held 59,490 shares of ARS Pharmaceuticals worth $478K as of Q2 2026.
  • AllianceBernstein bought 17,510 ARS Pharmaceuticals shares in Q2 2026, an estimated $151K.
  • ARS Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2745 holding.
  • AllianceBernstein first reported a position in ARS Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
  • AllianceBernstein's ARS Pharmaceuticals position peaked at $66.8M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.